E. Brendel

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Ahmad Awada, Alain Hendlisz, Thierry Gil et al. · British Journal of Cancer · 2005 · 338 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

Medicine, Oncology, Pharmacology +11

Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer

P. Kupsch, Bernhard F. Henning, K. Passarge et al. · Clinical Colorectal Cancer · 2005 · 115 citations

Medicine, Oncology, Pharmacotherapy +12

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

K. Mross, Simone Steinbild, F. Baas et al. · European Journal of Cancer · 2006 · 101 citations

Medicine, Pharmacokinetics, Pharmacology +8